Study of Chinese mRNA vaccine candidate shows booster raises effectiveness against Omicron

A new study has shown that a Chinese mRNA vaccine candidate saw a significant drop in its ability to neutralise the Omicron strand of the coronavirus compared to its effectiveness against a wild-type strain with no major mutations – but that a booster could readily induce the production of the neutralisation antibody.The vaccine, ARCoV, which is being jointly developed by the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology, is at the final stage of a…

Read the original article at South China Morning Post